In Vivo CRISPR Screens Identify E3 Ligase Cop1 As a Modulator of Macrophage Infiltration and Cancer Immunotherapy Target
bioRxiv preprint doi: https://doi.org/10.1101/2020.12.09.418012; this version posted December 10, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. In Vivo CRISPR Screens Identify E3 Ligase Cop1 as a Modulator of Macrophage Infiltration and Cancer Immunotherapy Target Xiaoqing Wang1,2,3,4,10, Collin Tokheim2,3,4,10, Binbin Wang2,10, Shengqing Stan Gu1,2,3,4,10, Qin Tang1,2,4,5, Yihao Li1,4, Nicole Traugh2,6, Yi Zhang2,3,4, Ziyi Li2, Boning Zhang1,2,3,4, Jingxin Fu2,3, Tengfei Xiao1,4, Wei Li2,3,4,7, Clifford A. Meyer2,3,4, Jun Chu2,8, Peng Jiang2,3,4,9, Paloma Cejas4, Klothilda Lim4, Henry Long4, Myles Brown1,4,*, and X. Shirley Liu2,3,4,* 1, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215. 2, Department of Data Science, Dana-Farber Cancer Institute, Boston, MA 02215. 3, Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA 02215. 4, Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215. 5, Current address: Salk Institute for Biological Studies, San Diego, CA 92037. 6, Current address: Graduate School of Biomedical Sciences, Tufts University, Boston, MA 02111. 7, Current address: Children's National Medical Center, George Washington University, Washington, DC 20010. 8, Key Laboratory of Xin'an Medicine, Ministry of Education, Anhui University Of Chinese Medicine, Hefei, Anhui, China, 230038. 9, Current address: Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892 10, These authors contributed equally.
[Show full text]